Mallinckrodt (Mallinckrodt) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Mallinckrodt is: No Data: Cannot be evaluated.

Competitive Comparison of Mallinckrodt's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mallinckrodt's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Risk Assessment falls into.

Mallinckrodt (OTCPK:MCKPF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Mallinckrodt Risk Assessment Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Mallinckrodt (Mallinckrodt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15

Website

https://www.mallinckrodt.com

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

Executives

Alta Fundamental Advisers Llc	10 percent owner	1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson	officer: EVP & Head of Corp Development	106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat	director
Paul Bisaro	director
Sigurdur O Olafsson	director, officer: President and CEO	360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch	officer: EVP & Head of Spec Generics	18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson	officer: EVP & Chief Scientific Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French	officer: EVP & Chief Commercial Officer	301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall	officer: EVP & Chief Legal Offi & Secre	1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen	officer: EVP & Chief Transformation OFC	202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF